Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 610-619

  Uchino, Keita ^a,b   Takeshita, Fumitaka ^a   Takahashi, Ryou U ^a   Kosaka, Nobuyoshi ^a   Fujiwara, Kae ^c   Naruoka, Haruna ^c   Sonoke, Satoru ^c   Yano, Junichi ^c   Sasaki, Hideo ^d   Nozawa, Shiari ^d   Yoshiike, Miki ^d   Kitajima, Kazuki ^d   Chikaraishi, Tatsuya ^d   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c NIPPON SHINYAKU CO LTD   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LEUCINE RICH REPEAT KINASE 2; MICRORNA; MICRORNA 582 3P; MICRORNA 582 5P; SINGLE STRANDED RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CHROMOSOME LOSS; CONTROLLED STUDY; DIX DOMAIN CONTAINING 1 GENE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUCINE RICH REPEAT KINASE 2 GENE; LIPOSOMAL DELIVERY; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PROTEIN GERANYLGERANYLTRANSFERASE TYPE 1 BETA SUBUNIT GENE; RNA INTERFERENCE;

ANIMALIA;

EID: 84875216772     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.269     Document Type: Article

References (46)

1. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
2. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
3. Aigner, A (2007). Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76: 9-21.
4. Takeshita, F and Ochiya, T (2006). Therapeutic potential of RNA interference against cancer. Cancer Sci 97: 689-696.
5. Gingrich, JR (2011). Bladder cancer: chemohyperthermia for bladder cancer-clinically effective? Nat Rev Urol 8: 414-416.
6. Pasin, E, Josephson, DY, Mitra, AP, Cote, RJ and Stein, JP (2008). Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10: 31-43.
7. Nogawa, M, Yuasa, T, Kimura, S, Tanaka, M, Kuroda, J, Sato, K et al. (2005). Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115: 978-985.
8. Seth, S, Matsui, Y, Fosnaugh, K, Liu, Y, Vaish, N, Adami, R et al. (2011). RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 19: 928-935.
9. Richter, J, Beffa, L, Wagner, U, Schraml, P, Gasser, TC, Moch, H et al. (1998). Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 153: 1615-1621.
10. Blaveri, E, Brewer, JL, Roydasgupta, R, Fridlyand, J, DeVries, S, Koppie, T et al. (2005). Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11(19 Pt 1): 7012-7022.
11. Caballi, MR, Egozcue, J, Gelabert, A, Prat, E and Bernue, M (2001). Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 4295: 5-11.
12. Calin, GA, Sevignani, C, Dumitru, CD, Hyslop, T, Noch, E, Yendamuri, S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004.
13. Rossi, S, Sevignani, C, Nnadi, SC, Siracusa, LD and Calin, GA (2008). Cancerassociated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome 19: 526-540.
14. Sevignani, C, Calin, GA, Nnadi, SC, Shimizu, M, Davuluri, RV, Hyslop, T et al. (2007). MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA 104: 8017-8022.
15. Calin, GA, Dumitru, CD, Shimizu, M, Bichi, R, Zupo, S, Noch, E et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529.
16. Yamada, H, Yanagisawa, K, Tokumaru, S, Taguchi, A, Nimura, Y, Osada, H et al. (2008). Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 47: 810-818.
17. Agueli, C, Cammarata, G, Salemi, D, Dagnino, L, Nicoletti, R, La Rosa, M et al. (2010). 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol 85: 575-578.
18. Weiss, GJ, Bemis, LT, Nakajima, E, Sugita, M, Birks, DK, Robinson, WA et al. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19: 1053-1059.
19. Takeshita, F, Patrawala, L, Osaki, M, Takahashi, RU, Yamamoto, Y, Kosaka, N et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
20. Hurst, CD, Fiegler, H, Carr, P, Williams, S, Carter, NP and Knowles, MA (2004). High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 23: 2250-2263.
21. Cordon-Cardo, C (1998). Molecular alterations in bladder cancer. Cancer Surv 32: 115-131.
22. Wada, T, Louhelainen, J, Hemminki, K, Adolfsson, J, Wijkström, H, Norming, U et al. (2001). The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. BJU Int 87: 876-881.
23. Polascik, TJ, Cairns, P, Chang, WY, Schoenberg, MP and Sidransky, D (1995). Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 55: 5396-5399.
24. Richter, J, Jiang, F, Görög, JP, Sartorius, G, Egenter, C, Gasser, TC et al. (1997). Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57: 2860-2864.
25. Griffiths-Jones, S, Grocock, RJ, van Dongen, S, Bateman, A and Enright, AJ (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34(Database issue): D140-D144.
26. Almal, SH and Padh, H (2012). Implications of gene copy-number variation in health and diseases. J Hum Genet 57: 6-13.
27. Sakurai, K, Furukawa, C, Haraguchi, T, Inada, K, Shiogama, K, Tagawa, T et al. (2011). MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 71: 1680-1689.
28. Zhang, T, Luo, Y, Wang, T and Yang, JY (2012). MicroRNA-297b-5p/3p target Mllt3/Af9 to suppress lymphoma cell proliferation, migration and invasion in vitro and tumor growth in nude mice. Leuk Lymphoma 53: 2033-2040.
29. Farh, KK, Grimson, A, Jan, C, Lewis, BP, Johnston, WK, Lim, LP et al. (2005). The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817-1821.
30. Baek, D, Villén, J, Shin, C, Camargo, FD, Gygi, SP and Bartel, DP (2008). The impact of microRNAs on protein output. Nature 455: 64-71.
31. Goff, LA, Davila, J, Swerdel, MR, Moore, JC, Cohen, RI, Wu, H et al. (2009). Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS ONE 4: e7192.
32. Wang, WX, Wilfred, BR, Hu, Y, Stromberg, AJ and Nelson, PT (2010). Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA 16: 394-404.
33. Tsuchiya, N, Izumiya, M, Ogata-Kawata, H, Okamoto, K, Fujiwara, Y, Nakai, M et al. (2011). Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 71: 4628-4639.
34. Kusama, T, Mukai, M, Tatsuta, M, Matsumoto, Y, Nakamura, H and Inoue, M (2003). Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis 20: 561-567.
35. Virtanen, SS, Sandholm, J, Yegutkin, G, Kalervo Väänänen, H and Härkönen, PL. (2011). Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. Cell Biol Int 34: 815-826.
36. Pan, T, Li, X and Jankovic, J (2011). The association between Parkinson's disease and melanoma. Int J Cancer 128: 2251-2260.
37. Ohta, E, Kawakami, F, Kubo, M and Obata, F (2011). LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585: 2165-2170.
38. Wang, L, Cao, XX, Chen, Q, Zhu, TF, Zhu, HG and Zheng, L (2009). DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci 100: 1801-1808.
39. Wang, X, Zheng, L, Zeng, Z, Zhou, G, Chien, J, Qian, C et al. (2006). DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochem Biophys Res Commun 347: 22-30.
40. Wang, JS, Wang, FB, Zhang, QG, Shen, ZZ and Shao, ZM (2008). Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res 6: 372-382.
41. Akavia, UD, Litvin, O, Kim, J, Sanchez-Garcia, F, Kotliar, D, Causton, HC et al. (2010). An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
42. Ostrowski, M, Carmo, NB, Krumeich, S, Fanget, I, Raposo, G, Savina, A et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 12: 19-30; sup pp 1.
43. Peltier, HJ and Latham, GJ (2008). Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852.
44. Watanabe, T, Shinohara, N, Sazawa, A, Harabayashi, T, Ogiso, Y, Koyanagi, T et al. (2000). An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7: 1575-1580.
45. Tanaka, M, Gee, JR, De La Cerda, J, Rosser, CJ, Zhou, JH, Benedict, WF et al. (2003). Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol 170: 975-978.
46. Horiguchi, Y, Kikuchi, E, Ozu, C, Nishiyama, T, Oyama, M, Horinaga, M et al. (2008). Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments. Hum Cell 21: 57-63.